Experience with the carbamylated monomeric allergoid Lais® for sublingual immunotherapy in patients with grass pollen or mite-induced allergic rhinoconjunctivitis
- Authors: Danilycheva IV1, Ilina NI1, Shulzhenko AE1
-
Affiliations:
- Institute of Immunology
- Issue: Vol 12, No 1 (2015)
- Pages: 60-64
- Section: Articles
- URL: https://bakhtiniada.ru/raj/article/view/120860
- DOI: https://doi.org/10.36691/RJA497
- ID: 120860
Cite item
Open Access
Access granted
Subscription Access
Abstract
The article presents the results of a prospective noncomparative study of carbamylated monomeric allergoid Lais ® for sublingual immunotherapy (SLIT) in patients with allergic rhinoconjunctivitis caused by pollen grasses. We suggest that SLIT using Lais ® sublingual tablets is an effective and well-tolerated method of treatment.
Full Text
##article.viewOnOriginalSite##About the authors
I V Danilycheva
Institute of Immunology
Email: ivdanilycheva@mail.ru
г. Москва
N I Ilina
Institute of Immunologyг. Москва
A E Shulzhenko
Institute of Immunologyг. Москва
References
- Lombardi C., Gargioni S., Melchiorre A. et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: Multicenter post-marketing surveillance study. J. Allergy. 2001, v. 56, p. 989-992.
- Quercia O., Bruno M.E., Compalati E. et al. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens. J. Eur. Ann. Allergy Clin. Immunol. 2011, v. 43, p. 176-183.
- Mösges R., Ritter B., Kayoko G. et al. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets. J. Acta Dermatoven. APA. 2010, v. 19, p. 3-10.
- Гущин И.С., Курбачева О.М. Аллергия и аллергенспецифическая иммунотерапия. М., «Фармарус Принт Медиа». 2010, 228 с.
- Passalacqua G., Albano M., Fregonese L. et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. J. Lancet. 1998, v. 351, p. 629-632.
- Rossi R.E., Monasterolo G. Safety of ultra-rush (two hours) sublingual swallow immunotherapy in allergic patients. J. Giorn. it allergol. immunol. clin. 2002, v. 12, p. 221-226.
- Agostinis F., Foglia C., Bruno M.E., Falagiani P. Efficacy, safety and tolerability of sublingual monomeric allergoid in tablets given without up-dosing to pediatric patients with allergic rhinitis and/or asthma due to grass pollen. Eur. Ann. Allergy Clin. Immunol. 2009, v. 41, p. 177-180.
- Passali D., Mosges R., Passali G.C. et al. Safety, tolerability, and efficacy of sublingual allergoid immunotherapy with three different shortened up-dosing administration schedules. J. Acta Otorhinolaryngologica Italica. 2010, v. 30, p. 131-137.
- Giordano T., Quarta C., Bruno M.E. et al. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase. J. Eur. Ann. Allergy Clin. Immunol. 2006, v. 38, p. 310-312.
- Agostinis F., Tellarini L., Canonica G.W. et al. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. J. Allergy. 2005, v. 60, p. 133.
Supplementary files
